## 1. Introduction

### 1.1 The NIL Market Gap

The 2021 NCAA interim NIL policy created a new asset class: endorsement and revenue streams attributable to collegiate athletes' Name, Image, and Likeness rights [@ncaa_nil_2021]. As of early 2026, the market exceeds \$1.1 billion in annual deal value, yet no standardized underwriting framework exists for securitizing these cash flows. Traditional credit models are structurally inadequate because:

1. **No credit history.** Athletes are typically 18–22 years old and possess no FICO-equivalent score or established repayment record.
2. **Non-linear career risk.** Injury, transfer portal entry, early draft declaration, and suspension each discretely reshape revenue trajectories in ways that smooth probability distributions do not capture.
3. **Sponsor concentration.** Revenue frequently depends on two to three sponsor relationships, introducing counterparty risk absent in diversified consumer credit.
4. **Eligibility entanglement.** NCAA compliance, conference realignment, and the patchwork of state-level SPARTA statutes create regulatory risk unique to this asset class [@sparta_2023].
5. **Reputational alpha.** Social media engagement quality, brand safety classification, and community standing materially affect deal origination and renewal—factors that have no analog in conventional lending.

These gaps mean that institutional investors lack a transparent, auditable, and reproducible methodology for evaluating NIL-backed securities. Without such a framework, capital allocation remains ad hoc, pricing is opaque, and secondary market development is stalled.

### 1.2 Contributions

NIL33 addresses these gaps with five primary contributions and two architectural extensions:

| # | Contribution | Section |
|---|---|---|
| 1 | A 33-signal, six-dimension scoring taxonomy covering the full credit surface of athlete NIL revenue | §3 |
| 2 | Instrument-sensitive dimension weighting with per-signal override capability | §4 |
| 3 | Automated covenant generation and risk flag detection tied to the scoring engine | §5 |
| 4 | Seeded Monte Carlo VaR with correlated dimension shocks | §6 |
| 5 | Cryptographic model identity (Genome Signature) enabling bit-exact reproducibility | §3 |
| 6 | Genome-stamped capital lifecycle objects (instruments, distributions, underwriting runs) | §7 |
| 7 | Portfolio genome analytics: homogeneity indexing, drift detection, and mutation risk scoring | §8 |

Contributions 1–5 constitute the core engine; contributions 6–7 extend the genome concept from a static fingerprint to a live provenance and evolutionary analytics layer.

### 1.3 Design Principles

The engine is built on four invariants:

- **Pure.** Every function is a pure function. No side effects, no network calls, no mutable state. The engine can run in any JavaScript runtime without modification.
- **Deterministic.** Identical inputs combined with the same genome produce identical outputs. There are no stochastic elements except the explicitly seeded Monte Carlo engine, which is itself deterministic given a fixed seed.
- **Hashable.** The entire model specification reduces to a single 128-bit genome ID via SHA-256 component hashing. Any change to any model parameter—signal definitions, weight profiles, grade thresholds, stress scenarios, covenant rules, flag rules, or valuation curves—produces a new genome ID.
- **Testable.** 75 automated tests validate every layer, including synthetic verification vectors that detect behavioral drift. All tests execute in under 500 ms with zero mocks or external dependencies.

### 1.4 Paper Organization

Section 2 surveys related work. Section 3 presents the genome methodology: signal ontology, canonical serialization, and SHA-256 identity derivation. Section 4 describes the scoring engine and grade assignment. Section 5 covers covenant generation and risk flags. Section 6 presents the stress testing and Monte Carlo VaR framework. Section 7 introduces lifecycle integration—the mechanism by which genome identity propagates through underwriting runs, instruments, and distributions. Section 8 describes portfolio genome analytics. Section 9 covers the reproducibility architecture. Section 10 discusses limitations and future work. Appendix A provides the public API surface and JSON schema examples.
